Wegovy sales figures and what they mean for your treatment

The big misconception: high sales does not mean freely available

The sales numbers for semaglutide are genuinely striking. Novo Nordisk has reported Wegovy as one of its fastest-growing products globally, and the trajectory of Wegovy's annual sales has been widely covered in the financial press. That scale creates a reasonable impression that this medicine is easy to obtain. It isn't, not legally, anyway.

In the UK, Wegovy is classified as a Prescription-Only Medicine. That status doesn't change with demand. A GPhC-registered prescriber must assess each patient individually, every time. No online quiz, no subscription sign-up, and no discount code changes that requirement. If you've come across a Wegovy sale that promises significant discounts, it's worth understanding what a compliant offer actually includes before placing an order. Some of those sellers are supplying counterfeit pens, the MHRA has warned publicly about fake weight-loss injections circulating online, with large enforcement actions throughout 2024 and 2025 targeting illegal manufacturers and traders. The popularity of semaglutide has made it a target.

The practical check you can do in under a minute: visit the GPhC pharmacy register and search any online pharmacy's name before placing an order. If it isn't listed, walk away. That single step filters out a significant proportion of counterfeit risk without any specialist knowledge.

So yes, Wegovy sales in 2025 reached levels that tell you the evidence is solid and clinician confidence is growing. It doesn't make the medicine available without proper assessment, and it doesn't justify prices that look suspiciously low.

What the semaglutide sales boom reflects: real-world evidence catching up with trials

The commercial growth of Wegovy tracks closely with the clinical evidence accumulating behind semaglutide. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, results that shifted how clinicians think about pharmacological weight management.

Since then the picture has filled in further. In January 2026, the MHRA approved a higher 7.2mg maintenance dose, and by April 2026 a dedicated single-dose 7.2mg pen had received authorisation, with trial data showing average weight loss approaching 20.7% over 72 weeks. That approval moved Wegovy's ceiling meaningfully closer to tirzepatide's results in the highest-dose trials. You can read more about how semaglutide works as a medicine and how the dose schedule progresses.

NICE recommended Wegovy under TA875 for adults with a BMI of 35 or above (with at least one weight-related condition), within specialist weight management services, for a maximum of two years. NHS waiting lists under that pathway are often long. The surge in private prescriptions reflects, in large part, patients who don't meet the current NHS thresholds or can't wait, not patients taking a shortcut. A clinician still reviews every case.

For a fuller picture of how private access works alongside the NHS route, the Wegovy treatment overview covers eligibility, the titration schedule, and what to expect from a private consultation.

Why sales data doesn't help you find a cheaper prescription

It's understandable to wonder whether Wegovy's scale means prices will fall, or that competition has driven discounts somewhere. The honest position: for a prescription medicine in the UK, any headline price has to account for the clinical assessment, the prescription itself, dispensing by a GPhC-registered pharmacy, and post-prescription aftercare. Providers who advertise prices significantly below the private market norm are typically excluding one or more of those components, or, in the worst cases, not sourcing from the licensed UK supply chain at all.

Eli Lilly adjusted the UK list price of Mounjaro (tirzepatide) upward from September 2025, and tracking semaglutide sales through 2025 shows that private pricing broadly reflects the costs of regulated dispensing rather than commercial competition. Comparing prices across providers is reasonable, but the comparison should include what each price actually covers, not just the headline per-pen figure.

At our pharmacy, one transparent price includes the clinical consultation, the prescription, the medicine itself, and free next-working-day delivery via DPD. There are no subscription fees and no auto-renewals. Every repeat order gets a fresh clinical review. That's a different proposition from a provider competing purely on price. For a sense of how private treatment costs are structured in the UK, the weight-loss treatments page sets out what's included without hidden extras.

The NHS and semaglutide: access is expanding, but slowly

Part of why private Wegovy sales have grown so fast is the gap between who qualifies clinically and who qualifies under current NHS commissioning. NICE recommends semaglutide through TA875, but the NHS pathway requires specialist weight management services and a maximum two-year treatment window. NHS England's phased rollout of tirzepatide under TA1026, meanwhile, is reaching more patients through GP practices from 2026, but it doesn't cover Wegovy directly.

Scotland, Wales and Northern Ireland commission on different thresholds and timelines. If you're trying to understand weight management treatment options more broadly (including what's available on the NHS versus privately) that page covers the landscape without assuming you've already made a decision. A prescriber at our clinical team can also advise on which treatment is likely to suit your circumstances, based on your health history, not a checklist.

The demand driving semaglutide's sales figures is real. So is the clinical basis for it. What matters for any individual patient isn't the global revenue number, it's whether treatment is appropriate for them, sourced safely, and supported properly once it starts.